Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Non-aspirin NSAIDs and head and neck cancer mortality in a Danish nationwide cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Parental occupational organic dust exposure and selected childhood cancers in Denmark 1968-2016

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Trends in thyroid cancer: Retrospective analysis of incidence and survival in Denmark 1980-2014

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Anaplastic thyroid carcinoma in Denmark 1996-2012: A national prospective study of 219 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Use of antidepressants and endometrial-cancer risk: a nationwide nested case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Survival in Women Diagnosed With Breast Cancer During Pregnancy

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Evidence suggests that non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) have antineoplastic properties of potential importance for survival of head and neck cancer.

METHODS: We conducted a nationwide cohort study including all individuals with primary head and neck squamous cell carcinoma in Denmark during 2000-2016 at age 30-84 years, with no history of cancer (except non-melanoma skin cancer), and alive at 1 year after diagnosis. Nationwide registries provided information on drug use, causes of death and potential confounders, and additional clinical information was obtained for a subpopulation. We conducted Cox proportional hazards regression to estimate multivariable-adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for the association between post-diagnosis non-aspirin NSAID use (defined as ≥1 filled prescription within first year after diagnosis) and cancer-specific mortality.

RESULTS: Among 10,770 head and neck cancer 1-year survivors, the HR for cancer-specific mortality with non-aspirin NSAID use was 1.68 at 1 year after diagnosis, but declined and stabilized around 1.15 (95% CI 1.02-1.29) at 2 years after diagnosis. Among 2-year survivors, the HRs for cancer-specific mortality with non-aspirin NSAID use remained slightly increased in analyses stratified by age, sex, stage, and pre-diagnosis non-aspirin NSAID use. Similar results were seen in the subpopulation (n = 1029) with additional clinical information, and among 5-year survivors with additional non-aspirin NSAID exposure assessment.

CONCLUSION: In this nationwide cohort of patients with head and neck cancer, use of non-aspirin NSAIDs was associated with a slightly increased mortality risk, warranting further evaluation.

Original languageEnglish
Article number102121
JournalCancer epidemiology
Volume77
ISSN1877-7821
DOIs
Publication statusPublished - Apr 2022

Bibliographical note

Copyright © 2022 Elsevier Ltd. All rights reserved.

    Research areas

  • Head and neck cancer, Human papillomavirus, Non-steroidal anti-inflammatory drugs, Oropharyngeal cancer, Survival

ID: 76237032